Abstract
Introduction
Oral submucous fibrosis (OSF) is a chronic debilitating disease and premalignant condition of the oral cavity and is a serious public health issue in India and many parts of the world. The treatment is still elusive and empirical because of poorly understood etiopathogenesis, which is believed to be multifactorial including areca nut chewing, ingestion of chillies, genetic and immunologic processes, nutritional deficiencies, and many others. The present investigations was focused to understand the possible therapeutic interventions of anti-OSF agents in arecoline induced experimental in vitro model of OSF and clinical application of these anti-OSF agents in the restoration of various grade of the disease.
Materials and Methods
The 127 subjects were selected from patients who visited the OPD of Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, K.G. Medical University, Lucknow. Further the subjects were divided in two groups on the basis of clinical examination. Group-1 subjects showed presence of fibrosis bands in the labial and/or buccal mucosa, loss of elasticity, difficulty to open the mouth and had a habit chewing areca-nut in some form. Group-2 subjects had no habit of chewing areca-nut, were apparently healthy with no mucosal disorder. The samples were collected and were immediately transported to Indian Institute of Toxicology Research, Lucknow, for isolation and cultivation of primary cultures of mucosal fibroblast cells. Then isolation and cultivation of oral mucosal fibroblast, identification of non-cytotoxic doses of arecoline, real time PCR, immunocytochemistry, cytokine determination in culture cells, western blot analyses, functional activity of collagenase, lysyl oxidase enzyme activity, collagen beads assay, cyclooxygenase (COX-2) expression analysis was done.
Results and Conclusions
This study, shows that the reduction of phagocytic cells was strongly related to the arecoline levels in fibroblast culture when we exposed arecoline to normal oral mucosal cells (NOMC) and cells from OSF patient. An enhancement of phagocytic cells was observed following the pre exposure of cells to 1 μM dexamethasone, a glucocorticoids, In this study, histologic evidence is presented which supports the finding that COX-2 expression is upregulated in OSF specimens compared to normal oral submucosal cells. Strong immunostaining for COX-2 was detected in arecoline exposed NOMC and cells from OSF patient. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. The number of phagocytic cells and phagocytic activity in cultured human oral fibroblasts from OSF site was lower than the fibroblasts from the normal regions of the same person.
Similar content being viewed by others
References
Angadi PV, Rao SS (2011) Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg 15:1–9
Angadi PV, Rekha KP (2011) Oral submucous fibrosis: a clinicopathologic review of 205 cases in Indians. Oral Maxillofac Surg 15:15–19
Bolcato-Bellemin AL, Elkaim R, Abehsera A, Fausser JL, Haikel Y, Tenenbaum H (2000) Expression of mRNAs encoding for alpha and beta integrin subunits, MMPs, and TIMPs in stretched human periodontal ligament and gingival fibroblasts. J Dent Res 79:1712–1716
Canniff JP, Harvey W, Harris M (1986) Oral submucous fibrosis: its pathogenesis and management. Br Dent J 160:429–434
Chang YC, Tai KW, Cheng MH, Chou LS, Chou MY (1998) Cytotoxic and non-genotoxic effects of arecoline on human buccal fibroblasts in vitro. J Oral Pathol Med 27:68–71
Chang YC, Tsai CH, Tai KW, Yang SH, Chou MY, Lii CK (2002) Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 38:425–430
Chang YC, Yang SF, Tai KW, Chou MY, Hsieh YS (2002) Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol 38:195–200
Chen CC, Huang JF, Tsai CC (1995) In vitro production of interleukin-6 by human gingival, normal buccal mucosa, and oral submucous fibrosis fibroblasts treated with betel-nut alkaloids. Gaoxiong Yi Xue Ke Xue Za Zhi 11:604–614
Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ (2002) Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev 11:646–653
Chou DH, Lee W, McCulloch CA (1996) Alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. J Immunol 156:4354–4362
Cox SC, Walker DM (1996) Oral submucous fibrosis. A review. Aust Dent J 41:294–299
Deng YT, Chen HM, Cheng SJ, Chiang CP, Kuo MY (2009) Arecoline-stimulated connective tissue growth actor production in human buccal mucosal fibroblasts: modulation by curcumin. Oral Oncol 45:99–105
Desmoulière A, Rubbia-Brandt L, Abdiu A, Walz T, Macieira-Coelho A, Gabbiani G (1992) Alpha-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by gamma-interferon. Exp Cell Res 201:64–73
Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111–122
Hardie J (1987) Oral submucous fibrosis. A review with case reports. J Can Dent Assoc 53:389–393
Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1998) Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 25:308–313
Hazarey VK, Erlewad DM, Mundhe KA, Ughade SN (2007) Oral submucous fibrosis: study of 1000 cases from central India. J Oral Pathol Med 36:12–17
Jeng JH, Ho YS, Chan CP, Wang YJ, Hahn LJ, Lei D, Hsu CC, Chang MC (2000) Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis 21:1365–1370
Kagan HM, Trackman PC (1991) Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5:206–210
Kovacs EJ (1991) Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 12:17–23
Ma RH, Tsai CC, Shieh TY (1995) Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. J Oral Pathol Med 24:407–412
Mansouri P, Yazdanian S, Safar F, Espandar R, Rezaii S, Safaie-Naraghi Z, Chalangari R (2010) Oral submucosal fibrosis in Iran: a case review. Int J Dermatol 49:1424–1428
Piguet PF, Grau GE, Vassalli P (1990) Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 136:103–110
Rajalalitha P, Vali S (2005) Molecular pathogenesis of oral submucous fibrosis—a collagen metabolic disorder. J Oral Pathol Med 34:321–328
Rajendran R (1994) Oral submucous fibrosis: etiology, pathogenesis, and future research. Bull World Health Organ 72:985–996
Ranganathan K, Devi MU, Joshua E, Kirankumar K, Saraswathi TR (2004) Oral submucous fibrosis: a case-control study in Chennai, South India. J Oral Pathol Med 33:274–277
Schmidt JA, Mizel SB, Cohen D, Green I (1982) Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol 128:2177–2182
Shah N, Sharma PP (1998) Role of chewing and smoking habits in the etiology of oral submucous fibrosis (OSF): a case-control study. J Oral Pathol Med 27:475–479
Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568
Trivedy C, Warnakulasuriya KA, Hazarey VK, Tavassoli M, Sommer P, Johnson NW (1999) The upregulation of lysyl oxidase in oral submucous fibrosis and squamous cell carcinoma. J Oral Pathol Med 28:246–251
Tsai CC, Ma RH, Shieh TY (1999) Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis. J Oral Pathol Med 28:59–63
Tseng SK, Chang MC, Su CY, Chi LY, Chang JZ, Tseng WY, Yeung SY, Hsu ML, Jeng JH (2012) Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells. Clin Oral Investig 16:1267–1273
Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. NJ Exp Med 163:632–643
Xia L, Tian-You L, Yi-Jun G, Dong-Sheng T, Wen-Hui L (2009) Arecoline and oral keratinocytes may affect the collagen metabolism of fibroblasts. J Oral Pathol Med 38:422–426
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, V., Mohammad, S., Pant, A.P. et al. Therapeutic Interventions in Oral Submucous Fibrosis: An Experimental and Clinical Study. J. Maxillofac. Oral Surg. 14, 278–290 (2015). https://doi.org/10.1007/s12663-014-0642-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12663-014-0642-8